With a flood of new followers coming to the SCRC board over the past couple days, I think it's important to reiterate for them (and everyone honestly) that the $4 price target frequently mentioned by Celtics is just the beginning for SCRC!!
$4 is not a price where the Core 100 are looking to sell. Everyone likes to have some numerical value to look forward to, and that's the purpose which this $4 price target serves. But in my opinion, it's only a short-term valuation for this company, which will quickly be surpassed in two years' time and will then be looked at as simply a stepping stone in SCRC's historic ascent.
Remember that Celtics is only factoring in one product (Pediatric RapiMed--think baby tylenol) in one market (USA) at one point in time (end of 2014) when he arrives at his price target of $4. And these 3 factors (discussed below) are exactly why this price should only be looked at as a step in the climb, and not the peak, of SCRC.
FACTOR #1: Increase In Sales of Pediatric RapiMed Over Time
Included in the $4 Price Target: $25 million in sales in 2014
But Remember: Sales of the Pediatric RapiMed product will increase significantly after its first year on the market once it begins to obtain some brand recognition with the general public, and parents begin to see that SCRC's product is superior to other brands of children's tylenol. We all know that simple word of mouth is one of the best and most contagious (no pun intended) forms of advertising--and who talks to each other more than parents.
Verdict: The $4 price target is based on $25 million in sales of Pediatric RapiMed in the USA, and that figure is only the beginning for this great product.
FACTOR #2: More Markets
Included in the $4 Price Target: Sales in the USA
But Remember: We live in a period of intense globalization, and there are sick children all over the world who could benefit from this SCRC product.
Verdict: The $4 price target is based only on sales in the USA, but there will be many more markets to explore down the road, including the country which holds about 20% of the world's population--China (China has a population that is over 4x the size of the USA).
FACTOR #3: More Products
Included in the $4 Price Target: Sales of Pediatric RapiMed
But Remember: The reason I've been saying Pediatric RapiMed (as opposed to RapiMeds) is that RapiMed is a product line of SCRC's of which the children's tylenol product is simply the first.
Verdict: The $4 price target is based only on sales of one product (Pediatric Rapimed), but RapiMeds is intended to be a whole product line which addresses other medical problems, including migraines and sleep deprivation (I believe sleeping pills are intended to be the next SCRC product). In addition, this price target does not factor in the potential of a generic viagra product frequently cited by CB.
FINAL VERDICT: All the reasons above are why you see so many of the SHOCKNAWE crew frequently cite SCRC as a once in a lifetime stock, akin to the next Amgen / Glaxo. It's not because of the short-term price target of $4. Rather, it's because of the long-term price potential of $50.
All current and future SCRC shareholders should know what they own and why they are here. I do. I plan on making $1 million+ with SCRC. I won't be scared into panic selling by little shakeouts because I'm mentally prepared for them and I've done my DD. I won't sell when we hit $1.50 simply because another group has alerted their members to that price objective because I know SCRC isn't a simple tag-and-go like other penny stocks. And I won't sell when we hit $4 because I know that $4 is just the beginning.
I know this is a strong board we have here, but I hope this helps some fellow SCRC shareholders maintain conviction in their purchase in the months and years ahead. Go SCRC!
